Avatrombopag is a thrombopoietin receptor agonist used to treat thrombocytopenia, a condition characterized by low platelet counts. It is indicated for two primary uses: (1) in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatments, and (2) in adult patients with chronic liver disease (CLD) who are scheduled to undergo a medical or dental procedure. Avatrombopag works by stimulating the production of platelets in the bone marrow, thereby increasing platelet counts and reducing the risk of bleeding. This medication is particularly beneficial for patients who cannot receive platelet transfusions or for whom transfusions are ineffective. It is administered orally, making it convenient, and its dosage is typically adjusted based on the patient’s platelet count and condition. By elevating platelet levels, avatrombopag helps ensure safer procedural outcomes and minimizes bleeding-related complications.